MedPath

Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis

Phase 4
Completed
Conditions
Endometriosis
Pelvic Pain
Interventions
Drug: dynamized estrogen
Drug: placebo
Registration Number
NCT02427386
Lead Sponsor
University of Sao Paulo General Hospital
Brief Summary

Endometriosis is a chronic inflammatory disease that causes pelvic pain difficult to treat. In view of this, many patients seek assistance in complementary and alternative medicine, including homeopathic treatment. The absence of evidence in the literature raises controversy about the effectiveness of homeopathic treatment in endometriosis. The aim of this randomized trial is to evaluate the effectiveness of dynamized estrogen compared to placebo in the treatment of chronic pelvic pain of endometriosis.

Detailed Description

This is a randomized, double-blind and placebo controlled trial using individualised homeopathic medicine (dynamized estrogen) to treat chronic pelvic pain of endometriosis. Patients with endometriosis, chronic pelvic pain and a set of signs and symptoms similar to those of the estrogen adverse events will be recruited in the Sector of Endometriosis of the Clinical Division of Gynaecological of the Hospital das Clínicas of the Faculty of Medicine of the University of Sao Paulo. The selection process was carried out through the analysis of medical charts and self-completing of structured questionnaires. Satisfied the inclusion criteria, fifty patients were randomly and distributed to receive dynamized estrogen or placebo. The primary clinical outcome is the severity of the chronic pelvic pain. Statistical analysis will be by intention-to-treat and per protocol comparing homeopathic drug with placebo after 24 weeks of intervention.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
50
Inclusion Criteria

primary inclusion criteria:

  • aged between 18 and 45;
  • diagnosis of endometriosis (endometrial ectopia) confirmed by imaging test (MRI or TVUS) or laparoscopy (biopsy);
  • chronic pelvic pain refractory to conventional hormone treatments and with intensity ≥ 5 on the visual analog pain scale (VAS-Pain: 0-10 points);

secondary inclusion criteria:

  • symptomatic individualization of patients according to adverse events of estrogen (minimum syndrome of maximum value).
Exclusion Criteria
  • absence of clinical and laboratory diagnosis of menopause or
  • premature ovarian failure

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
dynamized estrogen in alcohol solutiondynamized estrogenDynamized estrogen (17-beta estradiol) in the 12cH, 24cH and 18cH potencies.
placebo (alcohol solution)placeboThis arm received alcohol solution during the 24-week study duration.
Primary Outcome Measures
NameTimeMethod
chronic pelvic pain (measured by visual analog scale (VAS-Pain)24 weeks (6 months)

chronic pelvic pain (dysmenorrhoea, dyspareunia, acyclic pelvic pain depth, cyclic intestinal change and cyclic urinary change) measured by visual analog scale (VAS-Pain)

Secondary Outcome Measures
NameTimeMethod
36-Item Short-Form Health Survey (SF-36)24 weeks (6 months)
© Copyright 2025. All Rights Reserved by MedPath